FDA to Review Extending Uses for AstraZeneca-Controlled Drug

Date : 01/06/2020 @ 12:51PM
Source : Dow Jones News
Stock : AstraZeneca PLC (AZN)
Quote : 47.85  -1.48 (-3.00%) @ 12:59AM
After Hours
Last Trade
Last $ 47.87 ▲ 0.02 (0.04%)

FDA to Review Extending Uses for AstraZeneca-Controlled Drug

AstraZeneca (NYSE:AZN)
Historical Stock Chart

2 Months : From Dec 2019 to Feb 2020

Click Here for more AstraZeneca Charts.

By Micah Maidenberg


AstraZeneca PLC (AZN) said regulators in the U.S. will consider extending uses of its drug Farxiga.

The company said Monday the U.S. Food and Drug Administration accepted a supplemental new-drug application for Farxiga, agreeing to conduct a priority review of the therapy.

Regulators, in the new review, will consider the drug's use to treat patients facing the risk of cardiovascular death or the worsening of heart failure in some patients.

Adults with type two diabetes treat that disease with Farxiga, according to a website for the drug.


Write to Micah Maidenberg at micah.maidenberg@wsj.com


(END) Dow Jones Newswires

January 06, 2020 07:36 ET (12:36 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Latest AZN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.